{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:26Z","timestamp":1778591426616,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/12\/2015\/HAE-BMS"],"award-info":[{"award-number":["45\/12\/2015\/HAE-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bcmd.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T02:20:39Z","timestamp":1553394039000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"77","author":[{"given":"Ramachandran Krishna","family":"Chandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayanan","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunnathur Murugesan","family":"Sakthivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raveendran Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumarapillai Mohanan Nair Jagathnath","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariharan","family":"Sreedharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2019.03.004_bb0005","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/sj.onc.1206620","article-title":"Chronic myelogenous leukemia molecular signature","volume":"22","author":"Nowicki","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161470","article-title":"ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines","volume":"11","author":"Eadie","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","author":"Gillet","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.semcancer.2006.07.015","article-title":"The Myc oncoprotein as a therapeutic target for human cancer","volume":"16","author":"Vita","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1947601910377495","article-title":"Myc roles in hematopoiesis and leukemia","volume":"1","author":"Delgado","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0040","series-title":"ASH Education Program Book","first-page":"436","article-title":"Chronic myeloid leukemia stem cells","volume":"vol. 2008","author":"Jamieson","year":"2008"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/524308","article-title":"The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias","volume":"2012","author":"Tzifi","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0050","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.1633833100","article-title":"Expression of BCR\/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias","volume":"100","author":"Jaiswal","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0055","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/1097-0142(20010601)91:11<1964::AID-CNCR1221>3.0.CO;2-B","article-title":"Expression of apoptosis proteins in chronic myelogenous leukemia","volume":"91","author":"Ravandi","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0060","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0065","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0070","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.tcb.2007.07.004","article-title":"The C\/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control","volume":"17","author":"Nerlov","year":"2007","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0075","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2011.140","article-title":"TAL1\/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells","volume":"25","author":"Cardoso","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2867-12-13","article-title":"Mutations increased overexpression of Notch1 in T-cell acute lymphoblastic leukemia","volume":"12","author":"Lin","year":"2012","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0085","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0090","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.leu.2404549","article-title":"Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase","volume":"21","author":"Diaz-Blanco","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0145-2126(97)00006-4","article-title":"Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase","volume":"21","author":"Handa","year":"1997","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0145-2126(98)00097-6","article-title":"c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia","volume":"22","author":"Jennings","year":"1998","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10428199809057542","article-title":"Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration","volume":"30","author":"Beck","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0110","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes \u03b2-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Coluccia","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte\u2013macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2407-12-303","article-title":"Wnt\/\u03b2-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia","volume":"12","author":"Corr\u00eaa","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0125","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0130","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/10428194.2010.533220","article-title":"Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types","volume":"52","author":"Racil","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0140","first-page":"29","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0145","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0150","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0155","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cellsig.2011.02.005","article-title":"Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1","volume":"23","author":"Yamada","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0160","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0165","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0170","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1002\/cncr.27568","article-title":"Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment","volume":"118","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0175","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.leukres.2008.01.016","article-title":"Altered gene expression in busulfan-resistant human myeloid leukemia","volume":"32","author":"Valdez","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0180","first-page":"5761","article-title":"Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin","volume":"62","author":"Nimmanapalli","year":"2002","journal-title":"J. Cancer Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0185","first-page":"4267","article-title":"BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells","volume":"9","author":"Tauchi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000369446","article-title":"Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy","volume":"133","author":"Ferreira","year":"2015","journal-title":"Acta Haematol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0195","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0200","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5\u2013dependent expression of Bcl-xL","volume":"191","author":"Horita","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0205","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/sj.leu.2402340","article-title":"High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)","volume":"16","author":"K\u00f6hler","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0210","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","article-title":"High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2\u2013dependent suppression of C\/EBP\u03b1-driven myeloid differentiation","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ng791","article-title":"BCR-ABL suppresses C\/EBP\u03b1 expression through inhibitory action of hnRNP E2","volume":"30","author":"Perrotti","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0220","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jjco\/hyv064","article-title":"Correlation of C\/EBP\u03b1 expression with response and resistance to imatinib in chronic myeloid leukaemia","volume":"45","author":"Kagita","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4172\/2329-6917.1000225","article-title":"HES-1 and CEBPA mRNA in chronic and late phase (accelerated and blast crisis) of chronic myeloid leukemia (CML) patients","volume":"5","author":"Rahmawati","year":"2017","journal-title":"J. Leuk."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/15384047.2015.1016662","article-title":"Hes1: a key role in stemness, metastasis and multidrug resistance","volume":"16","author":"Liu","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/srep31995","article-title":"UPF1 regulates myeloid cell functions and S100A9 expression by the hnRNP E2\/miRNA-328 balance","volume":"6","author":"Saul","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcmd.2019.03.004_bb0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0245","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/leu.2012.258","article-title":"C\/EBP\u03b2 promotes BCR\u2013ABL-mediated myeloid expansion and leukemic stem cell exhaustion","volume":"27","author":"Hayashi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2019.03.004_bb0250","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2005-08-3181","article-title":"Inducible activation of CEBPB, a gene negatively regulated by BCR\/ABL, inhibits proliferation and promotes differentiation of BCR\/ABL-expressing cells","volume":"107","author":"Guerzoni","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcmd.2019.03.004_bb0255","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2002-01-0043","article-title":"The effects of Bcr-Abl on C\/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate","volume":"101","author":"Schuster","year":"2003","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961930049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961930049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:23:07Z","timestamp":1778588587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961930049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":51,"alternative-id":["S107997961930049X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.03.004","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}